| Trial ID: | L1817 |
| Source ID: | NCT01062048
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Januvia Re-examination Study (MK-0431-181)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Sulfonylurea|BIOLOGICAL: Insulin
|
| Outcome Measures: |
Primary: Percentage of participants with any adverse experience, up to 14 days following cessation of treatment|Mean change in Hemoglobin A1c (HbA1c), 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment|Mean change in fasting plasma glucose (FPG), 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment|Mean change in 2hr-postprandial glucose (PPG), 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3483
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-10
|
| Completion Date: |
2013-07
|
| Results First Posted: |
|
| Last Update Posted: |
2016-02-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01062048
|
